Functional improvement of dystrophic muscle by myostatin blockade
- PMID: 12459784
- DOI: 10.1038/nature01154
Functional improvement of dystrophic muscle by myostatin blockade
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Similar articles
-
Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice.Anat Rec A Discov Mol Cell Evol Biol. 2005 Sep;286(1):814-22. doi: 10.1002/ar.a.20224. Anat Rec A Discov Mol Cell Evol Biol. 2005. PMID: 16078270
-
Myostatin propeptide-mediated amelioration of dystrophic pathophysiology.FASEB J. 2005 Apr;19(6):543-9. doi: 10.1096/fj.04-2796com. FASEB J. 2005. PMID: 15791004
-
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.Muscle Nerve. 2008 Mar;37(3):308-16. doi: 10.1002/mus.20920. Muscle Nerve. 2008. PMID: 18041051
-
The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle.Neuromuscul Disord. 2005 Feb;15(2):117-26. doi: 10.1016/j.nmd.2004.10.018. Epub 2005 Jan 11. Neuromuscul Disord. 2005. PMID: 15694133 Review.
-
Targeting myostatin for therapies against muscle-wasting disorders.Curr Opin Drug Discov Devel. 2008 Jul;11(4):487-94. Curr Opin Drug Discov Devel. 2008. PMID: 18600566 Review.
Cited by
-
Muscle-specific transgenic expression of porcine myostatin propeptide enhances muscle growth in mice.Transgenic Res. 2013 Oct;22(5):1011-9. doi: 10.1007/s11248-013-9709-4. Epub 2013 Mar 30. Transgenic Res. 2013. PMID: 23543410
-
Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.Am J Physiol Endocrinol Metab. 2015 Sep 15;309(6):E557-67. doi: 10.1152/ajpendo.00098.2015. Epub 2015 Jul 28. Am J Physiol Endocrinol Metab. 2015. PMID: 26219865 Free PMC article.
-
A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.J Transl Med. 2007 Sep 24;5:45. doi: 10.1186/1479-5876-5-45. J Transl Med. 2007. PMID: 17892583 Free PMC article.
-
Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice.J Physiol. 2006 Sep 1;575(Pt 2):645-56. doi: 10.1113/jphysiol.2006.108472. Epub 2006 Jun 22. J Physiol. 2006. PMID: 16793906 Free PMC article.
-
Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.JCI Insight. 2020 Jan 16;5(1):e133276. doi: 10.1172/jci.insight.133276. JCI Insight. 2020. PMID: 31830002 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous